Astrazeneca Pharma shares jump 3% after company gets CDSCO approval for import, sale of bladder cancer drug
AstraZeneca Pharma shares surged 3% today after the company received a key regulatory nod from India's Central Drugs Standard Control Organisation (CDSCO). The approval allows AstraZeneca to import and sell its cancer drug Durvalumab (branded as Imfinzi) in India for an additional use.
This new approval covers two dosage forms—120 mg/2.4 ml and 500 mg/10 ml—and expands Imfinzi's indication to treat adult patients with muscle invasive bladder cancer (MIBC). Specifically, the drug can now be used in combination with gemcitabine and cisplatin as a neoadjuvant (pre-surgery) treatment. After surgery (radical cystectomy), Imfinzi can continue as a standalone adjuvant (post-surgery) therapy.
The expanded label marks a significant milestone for AstraZeneca in India's oncology market, particularly in bladder cancer treatment. The company can now begin marketing Imfinzi for this new use, subject to any further clearances that may be needed.
Imfinzi is already approved globally for other cancer indications, including lung and biliary tract cancers. This latest CDSCO approval adds another layer to its growing clinical footprint in India.
AstraZeneca Pharma shares opened at ₹9,195.00 and touched a high of ₹9,650.50 during the day. The stock did not fall below its opening price, marking ₹9,195.00 as the low. Over the past year, the stock has seen a 52-week high of ₹10,691.00 and a low of ₹6,220.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
20 minutes ago
- Business Upturn
BGR Energy receives contract termination from TN Power Corp for major Chennai project worth Rs 2,600 crore
BGR Energy Systems has announced that it has received a termination letter from Tamil Nadu Power Generation Corporation Ltd (TNPGCL), formerly known as TANGEDCO. The termination relates to the ₹2,600.02 crore EPC contract awarded for the Balance of Plant (BOP) and allied civil works at the 1 x 800 MW North Chennai Super Critical Thermal Power Project, Stage III. The official termination order was dated July 18, 2025, and was received by the company on July 22, 2025. In the exchange filings, BGR Energy Systems shared, 'We hereby inform you that the company has received 'termination of contract' letter from Tamil Nadu Power Generation Corporation Ltd (TNGCPL) (erstwhile TANGEDCO). This is with respect to establishment of 1 x 800 MW North Chennai Super Critical Thermal Power Project, Stage III – Balance of Plant (BOP) package along with allied civil works EPC contract of value Rs 2600.02 Crores' According to the disclosure, TNPGCL cited key project obligations not being fulfilled, incomplete critical systems, and lapses in insurance renewals and guarantee extensions as the reasons behind the decision. BGR Energy, however, noted that the matter is currently under arbitration before the Hon'ble High Court of Madras and expressed hope for a favorable resolution. The company also clarified that the termination does not have any significant impact on its financials or operations at this stage. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
21 minutes ago
- Business Upturn
Rail Vikas Nigam signs MoU to expand presence in Oman
Rail Vikas Nigam Limited (RVNL) has entered into a Memorandum of Understanding (MoU) with Mr. Ashraf Gulam Mohmed Theba in the Sultanate of Oman. This MoU aims to strengthen RVNL's global footprint by focusing on business development, market research, and company representation in Oman. The MoU marks a step towards deeper collaboration and paves the way for new opportunities in the Middle East region, as RVNL explores potential projects and partnerships beyond India. In the meantime, on July 14, the company won a key contract from Delhi Metro Rail Corporation (DMRC) under the Delhi MRTS Phase-IV project. The ₹447.42 crore deal (inclusive of 18% GST) covers part design and construction of a 7.3-km viaduct stretching from Chainage 1202.782 M to 8501.25 M. The scope includes building platforms at seven metro stations—Pushp Vihar, Saket District Court, Pushpa Bhawan, Chirag Delhi, GK-1, Andrews Ganj, and Lajpat Nagar—along with pre-engineered structures. Completion is expected in 36 months. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Fast Company
30 minutes ago
- Fast Company
AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy. The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement. It will also upgrade the Anglo-Swedish drugmaker's U.S. clinical trial supply network and support ongoing investment in novel medicines. On Monday, AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from the U.S. The U.S. accounted for more than 40% of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market — the world's largest, worth $635 billion — before Trump's return to office. The move to scale up its U.S. footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes. Trump has called on pharma companies to make more of the medicines they sell in the U.S. within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the U.S. to fall to what other countries pay. CEO Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and 'equalize' with other countries effectively contributing more to research and development costs. 'The United States cannot build or carry the cost of R&D for the entire world,' he said. U.S. Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs. 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness,' said Lutnick in a statement issued by AstraZeneca. While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to 'get their act together' before any levies take effect. The company said that the timing and location of the announcement was linked to the U.S. policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place. The pledge is in addition to the $3.5 billion in investments the company announced in November 2024, the statement said. PLEDGES The $50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson, Novartis, and Sanofi. Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies. The new Virginia facility — the company's largest single manufacturing investment — will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said. The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the U.S. and has a global workforce of about 90,000. In January it scrapped plans to invest 450 million pounds ($607.1 million) in its vaccine manufacturing plant in northern England, citing a cut in government support. Earlier this month, The Times reported the company was considering moving its stock market listing from London, where it is the exchange's most valuable company worth 159 billion pounds, to the U.S. The company declined to comment.
